Citations

Mayo Clinic

Showing 10 of 108551 citations.

ARISE I Consensus Statement on the Management of Chronic Subdural Hematoma
Kan, Peter , Fiorella, David , Dabus, Guilherme , Samaniego, Edgar A. , Lanzino, Giuseppe , Siddiqui, Adnan H. , Chen, Huanwen , Khalessi, Alexander A. , Fifi, Johanna T , Bain, Mark, Wakhloo, Ajay K. , Roundtable, on behalf of the ARISE I Academic Industry, Fifi, Johanna T , Colby, Geoffrey P , Wakhloo, Ajay K , Fiorella, David , Siddiqui, Adnan H , Samaniego, Edgar A , Lanzino, Giuseppe , Dabus, Guilherme C. , Mendes Pereira, Vitor , Colby, Geoffrey P. , Arthur, Adam Stephen , Roundtable, on behalf of the ARISE I Academic Industry, Chen, Huanwen

Stroke | April 22, 2024 | Volume: 55 | Issue: 5 | Pages: 1438-1448

10.1161/strokeaha.123.044129 | PMID 38648281 Get It

ARISE (Aneurysm/AVM/cSDH Roundtable Discussion With Industry and Stroke Experts) organized a one-and-a-half day meeting and workshop and brought together representatives from academia, industry, and government to discuss the most promising approaches to improve outcomes for patients with chronic subdural hematoma (cSDH). The emerging role of middle meningeal artery embolization in clinical practice and the design of current and potential future trials were the primary focuses of discussion. Existing evidence for imaging, indications, agents, and techniques was reviewed, and areas of priority for study and key questions surrounding the development of new and existing treatments for cSDH were identified. Multiple randomized, controlled trials have met their primary efficacy end points, providing high-level evidence that middle meningeal artery embolization is a potent adjunctive therapy to the standard (surgical and nonsurgical) management of neurologically stable cSDH patients in terms of reducing rates of disease recurrence. Pooled data analyses following the formal conclusion and publication of these trials will form a robust foundation upon which guidelines can be strengthened for cSDH treatment modalities and optimal patient selection, as well as delineate future lines of investigation.
eLife Assessment: Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model
Rogers, Laura Q. , Rogers, Laura

No container title available | April 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.96925.1.sa3 Get It

Cell competition drives bronchiolization and pulmonary fibrosis.
Klinkhammer, Kylie , Lyu, Handeng, Yao, Changfu , Stripp, Barry R. , Warren, Rachel , Yao, Changfu , Stripp, Barry , De Langhe, Stijn P

No container title available | April 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4177351/v1 | PMID 38746309 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease arising from the maladaptive differentiation of lung stem cells into bronchial epithelial cells rather than into alveolar type 1 (AT1) cells, which are responsible for gas exchange. Here, we report that healthy lungs maintain their stem cells through tonic Hippo and β-catenin signaling, which promote Yap/Taz degradation and allow for low level expression of the Wnt target gene Myc. Inactivation of upstream activators of the Hippo pathway in lung stem cells inhibits this tonic β-catenin signaling and Myc expression and promotes their Taz mediated differentiation into AT1 cells. Vice versa, increased Myc in collaboration with Yap promotes the differentiation of lung stem cells along the basal and myoepithelial like lineages allowing them to invade and bronchiolize the lung parenchyma in a process reminiscent of submucosal gland development. Our findings indicate that stem cells exhibiting the highest Myc levels become supercompetitors that drive remodeling, whereas loser cells with lower Myc levels terminally differentiate into AT1 cells.
Unlocking the potential of artificial intelligence in electrocardiogram biometrics: age-related changes, anomaly detection, and data authenticity in mobile health platforms
Mangold, Kathryn, Carter, Rickey E. , Siontis, Konstantinos C. , López-Jiménez, Francisco , Asirvatham, Samuel J. , Friedman, Paul A. , Attia, Zachi I. , Mangold, Kathryn E , Lopez-Jimenez, Francisco , Attia, Zachi I , Asirvatham, Samuel J , Carter, Rickey E , Noseworthy, Peter A.

European Heart Journal - Digital Health | April 22, 2024 | Volume: 5 | Issue: 3 | Pages: 314-323

10.1093/ehjdh/ztae024 | PMID 38774362 Get It

Abstract Aims Mobile devices such as smartphones and watches can now record single-lead electrocardiograms (ECGs), making wearables a potential screening tool for cardiac and wellness monitoring outside of healthcare settings. Because friends and family often share their smart phones and devices, confirmation that a sample is from a given patient is important before it is added to the electronic health record. Methods and results We sought to determine whether the application of Siamese neural network would permit the diagnostic ECG sample to serve as both a medical test and biometric identifier. When using similarity scores to discriminate whether a pair of ECGs came from the same patient or different patients, inputs of single-lead and 12-lead medians produced an area under the curve of 0.94 and 0.97, respectively. Conclusion The similar performance of the single-lead and 12-lead configurations underscores the potential use of mobile devices to monitor cardiac health.
Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
Szuber, Natasha , Orazi, Attilio , Tefferi, Ayalew , Szuber, Natasha , Orazi, Attilio

American Journal of Hematology | April 22, 2024 | Volume: 99 | Issue: 7 | Pages: 1360-1387

10.1002/ajh.27321 | PMID 38644693 Get It

AbstractChronic neutrophilic leukemia (CNL) is a rare BCR::ABL1‐negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic “[MDS]/MPN with neutrophilia” per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death. The 2022 revised WHO classification conserved CNL diagnostic criteria of leukocytosis ≥25 × 109/L, neutrophils ≥80% with <10% circulating precursors, absence of dysplasia, and presence of an activating CSF3R mutation. ICC criteria are harmonized with those of other myeloid entities, with a key distinction being lower leukocytosis threshold (≥13 × 109/L) for cases CSF3R‐mutated. Criteria for aCML include leukocytosis ≥13 × 109/L, dysgranulopoiesis, circulating myeloid precursors ≥10%, and at least one cytopenia for MDS‐thresholds (ICC). In both classifications ASXL1 and SETBP1 (ICC), or SETBP1 ± ETNK1 (WHO) mutations can be used to support the diagnosis. Both diseases show hypercellular bone marrow due to a granulocytic proliferation, aCML distinguished by dysplasia in granulocytes ± other lineages. Absence of monocytosis, rare/no basophilia, or eosinophilia, <20% blasts, and exclusion of other MPN, MDS/MPN, and tyrosine kinase fusions, are mandated. Cytogenetic abnormalities are identified in ~1/3 of CNL and ~15–40% of aCML patients. The molecular signature of CNL is a driver mutation in colony‐stimulating factor 3 receptor—classically T618I, documented in >80% of cases. Atypical CML harbors a complex genomic backdrop with high rates of recurrent somatic mutations in ASXL1, SETBP1, TET2, SRSF2, EZH2, and less frequently in ETNK1. Leukemic transformation rates are ~10–25% and 30–40% for CNL and aCML, respectively. Overall survival is poor: 15–31 months in CNL and 12–20 months in aCML. The Mayo Clinic CNL risk model for survival stratifies patients according to platelets <160 × 109/L (2 points), leukocytes >60 × 109/L (1 point), and ASXL1 mutation (1 point); distinguishing low‐ (0–1 points) versus high‐risk (2–4 points) categories. The Mayo Clinic aCML risk model attributes 1 point each for: age >67 years, hemoglobin <10 g/dL, and TET2 mutation, delineating low‐ (0–1 risk factor) and high‐risk (≥2 risk factors) subgroups. Management is risk‐driven and symptom‐directed, with no current standard of care. Most commonly used agents include hydroxyurea, interferon, Janus kinase inhibitors, and hypomethylating agents, though none are disease‐modifying. Hematopoietic stem cell transplant is the only potentially curative modality and should be considered in eligible patients. Recent genetic profiling has disclosed CBL, CEBPA, EZH2, NRAS, TET2, and U2AF1 to represent high‐risk mutations in both entities. Actionable mutations (NRAS/KRAS, ETNK1) have also been identified, supporting novel agents targeting involved pathways. Preclinical and clinical studies evaluating new drugs (e.g., fedratinib, phase 2) and combinations are detailed.
Enhancing clinical decision‐making: Optimizing ChatGPT's performance in hypertension care
Miao, Jing , Fülöp, Tibor , Cheungpasitporn, Wisit , Fülöp, Tibor , Cheungpasitporn, Wisit , Miao, Jing , Thongprayoon, Charat

The Journal of Clinical Hypertension | April 22, 2024 | Volume: 26 | Issue: 5 | Pages: 588-593

10.1111/jch.14822 | PMID 38646920 Get It

USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization
Liu, Jiaqi , Zhu, Qian , Zhang, Yixin , Chen, Yuping , Wang, Kaikai , Lou, Zhenkun , Yuan, Jian

CNS Neuroscience & Therapeutics | April 22, 2024 | Volume: 30 | Issue: 4 | Pages: No page available

10.1111/cns.14711 | PMID 38644551 Get It

AbstractObjectiveTo elucidate the relationship between USP19 and O(6)‐methylguanine‐DNA methyltransferase (MGMT) after temozolomide treatment in glioblastoma (GBM) patients with chemotherapy resistance.MethodsScreening the deubiquitinase pannel and identifying the deubiquitinase directly interacts with and deubiquitination MGMT. Deubiquitination assay to confirm USP19 deubiquitinates MGMT. The colony formation and tumor growth study in xenograft assess USP19 affects the GBM sensitive to TMZ was performed by T98G, LN18, U251, and U87 cell lines. Immunohistochemistry staining and survival analysis were performed to explore how USP19 is correlated to MGMT in GBM clinical management.ResultsUSP19 removes the ubiquitination of MGMT to facilitate the DNA methylation damage repair. Depletion of USP19 results in the glioblastoma cell sensitivity to temozolomide, which can be rescued by overexpressing MGMT. USP19 is overexpressed in glioblastoma patient samples, which positively correlates with the level of MGMT protein and poor prognosis in these patients.ConclusionThe regulation of MGMT ubiquitination by USP19 plays a critical role in DNA methylation damage repair and GBM patients’ temozolomide chemotherapy response.
Injectable bioactive poly(propylene fumarate) and polycaprolactone based click chemistry bone cement for spinal fusion in rabbits
Liu, Xifeng , Potes, Maria Astudillo , Dashtdar, Babak , Schreiber, Areonna C., Rezaei, Asghar , Elder, Benjamin D. , Lu, Lichun , Astudillo Potes, Maria D, Serdiuk, Vitalii , Shafi, Mahnoor , Miller, Alan Lee , Hamouda, Abdelrahman M.

Journal of Biomedical Materials Research Part A | April 22, 2024 | Volume: 112 | Issue: 10 | Pages: 1803-1816

10.1002/jbm.a.37725 | PMID 38644548 Get It

AbstractDegenerative spinal pathology is a widespread medical issue, and spine fusion surgeries are frequently performed. In this study, we fabricated an injectable bioactive click chemistry polymer cement for use in spinal fusion and bone regrowth. Taking advantages of the bioorthogonal click reaction, this cement can be crosslinked by itself eliminating the addition of a toxic initiator or catalyst, nor any external energy sources like UV light or heat. Furthermore, nano‐hydroxyapatite (nHA) and microspheres carrying recombinant human bone morphogenetic protein‐2 (rhBMP‐2) and recombinant human vascular endothelial growth factor (rhVEGF) were used to make the cement bioactive for vascular induction and osteointegration. After implantation into a rabbit posterolateral spinal fusion (PLF) model, the cement showed excellent induction of new bone formation and bridging bone, achieving results comparable to autograft control. This is largely due to the osteogenic properties of nano‐hydroxyapatite (nHA) and the released rhBMP‐2 and rhVEGF growth factors. Since the availability of autograft sources is limited in clinical settings, this injectable bioactive click chemistry cement may be a promising alternative for spine fusion applications in addressing various spinal conditions.
Recommendation endpoints and safety of an online self-triage for depression symptoms
Miller, Nathaniel E. , North, Frederick , Curry, Elizabeth , Curry, Elizabeth N., Thompson, Matthew C , Pecina, Jennifer , Miller, Nathaniel E , Pecina, Jennifer L.

Journal of Telemedicine and Telecare | April 22, 2024 | Volume: 31 | Issue: 8 | Pages: 1186-1192

10.1177/1357633x241245161 | PMID 38646705 Get It

Introduction Online symptom checkers are a way to address patient concerns and potentially offload a burdened healthcare system. However, safety outcomes of self-triage are unknown, so we reviewed triage recommendations and outcomes of our institution's depression symptom checker. Methods We examined endpoint recommendations and follow-up encounters seven days afterward during 2 December 2021 to 13 December 2022. Patients with an emergency department visit or hospitalization within seven days of self-triaging had a manual review of the electronic health record to determine if the visit was related to depression, suicidal ideation, or suicide attempt. Charts were reviewed for deaths within seven days of self-triage. Results There were 287 unique encounters from 263 unique patients. In 86.1% (247/287), the endpoint was an instruction to call nurse triage; in 3.1% of encounters (9/287), instruction was to seek emergency care. Only 20.2% (58/287) followed the recommendations given. Of the 229 patients that did not follow the endpoint recommendations, 121 (52.8%) had some type of follow-up within seven days. Nearly 11% (31/287) were triaged to endpoints not requiring urgent contact and 9.1% (26/287) to an endpoint that would not need any healthcare team input. No patients died in the study period. Conclusions Most patients did not follow the recommendations for follow-up care although ultimately most patients did receive care within seven days. Self-triage appears to appropriately sort patients with depressed mood to emergency care. On-line self-triaging tools for depression have the potential to safely offload some work from clinic personnel.
The paraneurium and the tumefactive appearance of peripheral nerve neurolymphomatosis: illustrative case
Kendziora, Ryan W., Wismayer, David J. Schembri, Spinner, Robert J. , Schembri Wismayer, David J, Barone, Damiano G. , Broski, Stephen M.

Journal of Neurosurgery: Case Lessons | April 22, 2024 | Volume: 7 | Issue: 17 | Pages: No page available

10.3171/case24125 | PMID 38648674 Get It

BACKGROUND Peripheral neurolymphomatosis (NL) is an often-misdiagnosed condition characterized by lymphomatous infiltration within the peripheral nerves. Its rarity and complexity frequently result in delayed diagnosis and suboptimal patient outcomes. This study aims to elucidate the role of the paraneurium (circumneurium) in NL, emphasizing its diagnostic and therapeutic significance. OBSERVATIONS A 72-year-old man presented with lesions on his right lower eyelid. Initial diagnostics were inconclusive until an excisional biopsy confirmed extranodal marginal zone lymphoma. Following a complete metabolic response to rituximab treatment, the patient relapsed 14 months later with progressive lymphoma and bilateral sciatic nerve involvement, as confirmed by positron emission tomography–computed tomography and magnetic resonance imaging. LESSONS This paper underscores the critical role of the paraneurium in NL, enhancing understanding of its pathophysiology. Integrating advanced imaging techniques have proved essential in accurately identifying neurolymphomatous involvement within the paraneurium. This study paves the way for more effective management strategies in NL and similar conditions, focusing on improving patient care and outcomes.